Institution
Radboud University Nijmegen
Education•Nijmegen, Gelderland, Netherlands•
About: Radboud University Nijmegen is a education organization based out in Nijmegen, Gelderland, Netherlands. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 35417 authors who have published 83035 publications receiving 3285064 citations. The organization is also known as: Catholic University of Nijmegen & Radboud University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A consistent and descriptive nomenclature is suggested for reactors in which the anammox process is employed, and Reactors with a high specific surface area like the granular sludge reactor employed in Rotterdam provide the highest volumetric loading rates.
1,055 citations
••
Leeds General Infirmary1, Saarland University2, Johns Hopkins University3, University of Paris4, Radboud University Nijmegen5, University of Duisburg-Essen6, Royal Melbourne Hospital7, St George's Hospital8, City of Hope National Medical Center9, Trinity College, Dublin10, University of Naples Federico II11, University of Ulm12, Cleveland Clinic13, Case Western Reserve University14, Alexion Pharmaceuticals15
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Abstract: BACKGROUND We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS Eculizumab is an effective therapy for PNH.
1,051 citations
••
TL;DR: It is demonstrated that feedforward and feedback signaling use distinct frequency channels, suggesting that they subserve differential communication requirements.
1,043 citations
••
University of Bonn1, Charité2, Hannover Medical School3, University Hospital Bonn4, German Center for Neurodegenerative Diseases5, Leibniz Association6, Radboud University Nijmegen7, Max Delbrück Center for Molecular Medicine8, University of Hamburg9, Bernhard Nocht Institute for Tropical Medicine10
TL;DR: This study provides detailed insights into the systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the myeloid cell compartment associated with severe COVID-19.
1,042 citations
••
TL;DR: The weighted phase lag index (WPLI) as mentioned in this paper measures the contribution of the observed phase leads and lags by the magnitude of the imaginary component of the cross-spectrum.
1,041 citations
Authors
Showing all 35749 results
Name | H-index | Papers | Citations |
---|---|---|---|
Charles A. Dinarello | 190 | 1058 | 139668 |
Richard H. Friend | 169 | 1182 | 140032 |
Yang Gao | 168 | 2047 | 146301 |
Ian J. Deary | 166 | 1795 | 114161 |
David T. Felson | 153 | 861 | 133514 |
Margaret A. Pericak-Vance | 149 | 826 | 118672 |
Fernando Rivadeneira | 146 | 628 | 86582 |
Shah Ebrahim | 146 | 733 | 96807 |
Mihai G. Netea | 142 | 1170 | 86908 |
Mingshui Chen | 141 | 1543 | 125369 |
George Alverson | 140 | 1653 | 105074 |
Barry Blumenfeld | 140 | 1909 | 105694 |
Harvey B Newman | 139 | 1594 | 88308 |
Tariq Aziz | 138 | 1646 | 96586 |
Stylianos E. Antonarakis | 138 | 746 | 93605 |